NAPROXEN ORAL SUSPENSION, USP, 125 mg/5mL, Rx only, 16fl oz (473 mL) bottles, Distributed by: Acella Pharmaceuticals, LLC, Alpharetta, GA 30005, Made in Canada NDC 42192-619-16
Published May 13, 2026 · Recall initiated: April 20, 2026
Summary
FDA records drug Class II recall D-0523-2026, published May 13, 2026 and initiated April 20, 2026. Recalling firm: Acella Pharmaceuticals, LLC; Status: Ongoing; Reported quantity: 6,336 bottles; Lot: Lot: 23F02, Expires: 05/2026; 25A37, Expires: 01/2028. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Chemical contamination; presence of lead and lithium above specification
What to do
Voluntary: Firm initiated · Letter
Get an email if NAPROXEN has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- NAPROXEN
- Manufacturer
- Acella Pharmaceuticals, LLC
- Distributor
- Nationwide
- UPC
- 0342192619166
- Lot
- Lot: 23F02, Expires: 05/2026; 25A37, Expires: 01/2028.
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDADuloxetine Delayed-Release Capsules USP, 60mg, Rx Only, 90-count bottle, Mfr. by Towa Pharmaceutical EurpoeMay 13, 2026
- FDATPN bag (patient specific), Rx# 11-4909703-0-1, Compound Volume 1660 mL per bag, Rx only, Single DoseMay 13, 2026
- FDAEnalapril Maleate Tablets, USP, 20 mg, 1,000-count bottle, Rx only, Manufactured by: Unique PharmaceuticalMay 13, 2026
- FDALactated Ringer's Injection USP, 1000 mL container, Rx only, B. Braun Medical, Inc., Bethlehem, PA 18018-3524May 13, 2026
- FDAOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, In Single-Dose kitsMay 13, 2026
- FDAGarland Fresh Peeled Garlic 6 oz. bagMay 13, 2026
Questions about this recall
Was NAPROXEN ORAL SUSPENSION, USP, 125 mg/5mL, Rx only, 16fl oz (473 mL) bottles, Distributed by: Acella Pharmaceuticals, LLC, Alpharetta, GA 30005, Made in Canada NDC 42192-619-16 recalled?
Yes. FDA published recall D-0523-2026 on May 13, 2026. Reported hazard: Chemical contamination; presence of lead and lithium above specification
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: NAPROXEN. UPC: 0342192619166.